Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. From Wikipedia
The FDA designation expedites the development of survodutide, a promising dual receptor agonist, for treating non-cirrhotic MASH with moderate to advanced fibrosis.
